Alkermes Reports Phase 3 Study Results for Aripiprazole Lauroxil Published in JCP
June 09, 2015 at 16:01 PM EDT
Alkermes plc (NASDAQ: ALKS) today announced the publication of results from its phase 3 clinical trial of aripiprazole lauroxil for the ...
